Nishank Jain
Associate Professor
Also affiliated: Rush University Medical Center (2024); University of Arizona (2021); University of Connecticut (2008); University of Hartford (2008); University of Arkansas Medical Center (2016–2024); University of Alabama at Birmingham (2011); Pediatric Nephrology of Alabama (2012–2014); Central Arkansas Veterans Healthcare System (2017–2024); VA North Texas Health Care System (2012–2014); Rochester General Hospital (2026); Banner - University Medical Center Tucson (2021); University of Applied Management Studies (2024); University of Kansas Medical Center (2015–2016); The University of Texas Southwestern Medical Center (2011–2014)
Faculty Researcher
Internal Med, College of Medicine
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Nishank Jain, MD, MPH, is an Associate Professor in the Department of Internal Medicine at the University of Arkansas for Medical Sciences. His research focuses on the role of platelets in the pathophysiology of chronic kidney disease (CKD) and the application of antiplatelet agents in patients with kidney diseases. He has received funding for his work from the American Heart Association (AHA), an institutional KL2 grant, and career development grants from the American Society of Nephrology and the AHA.
Dr. Jain's scholarly output includes numerous publications examining platelet function, inflammation, and therapeutic interventions in CKD and dialysis populations. Recent work has investigated the comparative effectiveness and safety of oral P2Y12 inhibitors in patients undergoing chronic dialysis and explored the potential of antiplatelet therapy to reduce sepsis-related mortality in this group. His research also extends to renal biomarkers in heart failure.
With an h-index of 17 and over 1,200 citations across 66 publications, Dr. Jain is an active contributor to his field. He leads a research group and collaborates with several colleagues at the University of Arkansas for Medical Sciences, including Jawahar L. Mehta, Jerry Ware, Adam Corken, and Otis M. Davis. Dr. Jain is also dedicated to medical education, mentoring students and receiving teaching awards.
Research Overview
Nishank Jain, MD, MPH, is a nephrologist and an Associate Professor in the Department of Medicine at University of Arkansas for Medical Sciences, Little Rock, AR. He completed his clinical and research fellowship at UT Southwestern Medical Center, Dallas, TX, before joining as a faculty member. His research interest is in the role of platelets in CKD pathophysiology and use of antiplatelet agents in patients with kidney diseases. He has been funded by post-doctoral fellowship grant from the American Heart Association (AHA), institutional KL2 grant and career development grants from the American Society of Nephrology and the AHA. Dr. Jain is passionate about education and is driven by training and engaging medical students for a career in academic medicine. He has also helped medical students receive Honors in Research upon graduation. Dr. Jain has received medical student teaching awards. He has also engaged in SSCI activities by sending medical students to present original research work at the Annual Meetings.
Metrics
- h-index: 17
- Publications: 67
- Citations: 1,261
Selected Publications
-
Acute Kidney Injury in Recipients of Chimeric Antigen Receptor T-Cell Therapy: Clinical Characteristics and Impact on Mortality (2026)
-
GLP-1 Agonists and Risk of Atrial Fibrillation in Non-Dialysis Chronic Kidney Disease (2026)
-
Hydrocortisone Use for Septic Shock in Patients With CKD (2026)
-
Renal safety and clinical outcomes of enfortumab vedotin plus pembrolizumab in urothelial carcinoma patients with chronic kidney disease. (2026)
-
26-A-10911-ACC EFFECT OF GLUCAGON-LIKE RECEPTOR PEPTIDE-1 AGONISTS ON ATRIAL FIBRILLATION-RELATED EVENTS AND INCIDENCE IN CHRONIC KIDNEY DISEASE (2026)
-
Fungal DNA in Circulation (2025)
-
AKI in Patients Receiving Chimeric Antigen Receptor T Cells: Risk Factors and Characteristics (2025)
-
Hypophosphatemia as a Marker for Immune Effector Cell-Associated Neurotoxicity Syndrome in Chimeric Antigen Receptor T Cell Recipients (2025)
-
Sepsis-Related Hospitalization and Mortality in Patients with CKD (2025)
-
Left Atrial Appendage Occlusion vs Anticoagulants in Dialysis With Atrial Fibrillation (2025)
-
Potent P2Y12 Receptor Inhibitors Reduce Risk for Hospitalization from Sepsis in Patients with CKD (2025)
-
Higher Glycolysis in Circulating Leukocytes in Patients with CKD (2024)
-
Platelets, inflammation, and purinergic receptors in chronic kidney disease (2024)
-
P2Y12 Inhibitors Refill Gap Predicts Death in Medicare Beneficiaries on Chronic Dialysis (2024)
-
EFFICACY AND OUTCOMES OF LEFT ATRIAL APPENDAGE OCCLUSION IN PATIENTS WITH ATRIAL FIBRILLATION AND ESRD (2024)
Grants & Funding
As listed on this researcher's institutional profile.
- Glycolysis in Leukocytes and Inflammation in Patients with CKD Dialysis Clinic, Inc. Principal Investigator
- Platelet, Inflammation and Thrombosis in Chronic Kidney Disease NIH/NCATS Principle Investigator
- Platelet-Leukocyte Axis in Patients with Chronic Kidney Disease Dialysis Clinic, Inc. Principal Investigator
- Effectiveness and safety of clopidogrel, prasugrel and ticagrelor in patients with end stage renal disease (ESCALATE) American Heart Association Principal Investigator
- PREDICT-BLEED study Translational Research Institute, UAMS Principal Investigator
- A Mechanistic Study in Patients with Non-Dialysis Chronic Kidney Disease to Investigate Altered Platelet Response to Antiplatelet Therapy (CKD-Platelet Study) American Society of Nephrology Foundation for Kidney Research Principal Investigator
- Study of uremic toxins and levels of antiplatelet therapy to investigate mechanisms of excessive stroke in patients with chronic kidney disease UAMS Office of Research Principal Investigator
Collaboration Network
Top Collaborators
- Platelet-Dependent Inflammatory Dysregulation in Patients with Stages 4 or 5 Chronic Kidney Disease: A Mechanistic Clinical Study
- Ticagrelor inhibits platelet aggregation and reduces inflammatory burden more than clopidogrel in patients with stages 4 or 5 chronic kidney disease
- Comparative Effectiveness and Safety of Oral P2Y12 Inhibitors in Patients on Chronic Dialysis
- Potent Antiplatelet Therapy May Reduce Death from Sepsis in Patients on Chronic Dialysis
- Age Modifies Intracranial and Gastrointestinal Bleeding Risk from P2Y12 Inhibitors in Patients Receiving Dialysis
Showing 5 of 8 shared publications
- Platelet-Dependent Inflammatory Dysregulation in Patients with Stages 4 or 5 Chronic Kidney Disease: A Mechanistic Clinical Study
- Ticagrelor inhibits platelet aggregation and reduces inflammatory burden more than clopidogrel in patients with stages 4 or 5 chronic kidney disease
- Comparative Effectiveness and Safety of Oral P2Y12 Inhibitors in Patients on Chronic Dialysis
- Age Modifies Intracranial and Gastrointestinal Bleeding Risk from P2Y12 Inhibitors in Patients Receiving Dialysis
- P2Y12 Inhibitors Refill Gap Predicts Death in Medicare Beneficiaries on Chronic Dialysis
Showing 5 of 6 shared publications
- Role of Platelets in Chronic Kidney Disease
- Platelet-Dependent Inflammatory Dysregulation in Patients with Stages 4 or 5 Chronic Kidney Disease: A Mechanistic Clinical Study
- Ticagrelor inhibits platelet aggregation and reduces inflammatory burden more than clopidogrel in patients with stages 4 or 5 chronic kidney disease
- Platelet Count and Platelet Volume in Patients with CKD
- 438 Platelets, Inflammation and Thrombosis in Chronic Kidney Disease
- Role of Platelets in Chronic Kidney Disease
- Platelet-Dependent Inflammatory Dysregulation in Patients with Stages 4 or 5 Chronic Kidney Disease: A Mechanistic Clinical Study
- Ticagrelor inhibits platelet aggregation and reduces inflammatory burden more than clopidogrel in patients with stages 4 or 5 chronic kidney disease
- Platelet Count and Platelet Volume in Patients with CKD
- Authors' Reply: Platelet Count, Platelet Volume and CKD
- Ticagrelor inhibits platelet aggregation and reduces inflammatory burden more than clopidogrel in patients with stages 4 or 5 chronic kidney disease
- Comparative Effectiveness and Safety of Oral P2Y12 Inhibitors in Patients on Chronic Dialysis
- Screening for Cardiovascular Disease in CKD: PRO
- Age Modifies Intracranial and Gastrointestinal Bleeding Risk from P2Y12 Inhibitors in Patients Receiving Dialysis
- Depression and Other Psychological Issues in CKD
- Updates on New Therapies for Patients with CKD
- Platelet-Dependent Inflammatory Dysregulation in Patients with Stages 4 or 5 Chronic Kidney Disease: A Mechanistic Clinical Study
- Potent Antiplatelet Therapy May Reduce Death from Sepsis in Patients on Chronic Dialysis
- Age Modifies Intracranial and Gastrointestinal Bleeding Risk from P2Y12 Inhibitors in Patients Receiving Dialysis
- 438 Platelets, Inflammation and Thrombosis in Chronic Kidney Disease
- Updates on New Therapies for Patients with CKD
- Platelets, inflammation, and purinergic receptors in chronic kidney disease
- Platelet Count and Platelet Volume in Patients with CKD
- Authors' Reply: Platelet Count, Platelet Volume and CKD
- Higher Glycolysis in Circulating Leukocytes in Patients with CKD
- Role of Platelets in Chronic Kidney Disease
- Platelet-Dependent Inflammatory Dysregulation in Patients with Stages 4 or 5 Chronic Kidney Disease: A Mechanistic Clinical Study
- Platelets, inflammation, and purinergic receptors in chronic kidney disease
- Ticagrelor inhibits platelet aggregation and reduces inflammatory burden more than clopidogrel in patients with stages 4 or 5 chronic kidney disease
- Ticagrelor inhibits platelet aggregation and reduces inflammatory burden more than clopidogrel in patients with stages 4 or 5 chronic kidney disease
- Platelet Count and Platelet Volume in Patients with CKD
- Response to [Challenging the Restrictive Approach: Reconsidering SGLT-2 Inhibitor Use in CKD]
- Ticagrelor Is Superior to Clopidogrel in Inhibiting Platelet Aggregation in Patients With Stages 4-5 CKD
- Role of Platelets in Chronic Kidney Disease
- Platelet-Dependent Inflammatory Dysregulation in Patients with Stages 4 or 5 Chronic Kidney Disease: A Mechanistic Clinical Study
- Comparative Effectiveness and Safety of Oral P2Y12 Inhibitors in Patients on Chronic Dialysis
- Comparative Effectiveness and Safety of Oral P2Y12 Inhibitors in Patients on Chronic Dialysis
- Left Atrial Appendage Occlusion vs Anticoagulants in Dialysis With Atrial Fibrillation
- P2Y12 Inhibitors Refill Gap Predicts Death in Medicare Beneficiaries on Chronic Dialysis
- Comparative Effectiveness and Safety of Oral P2Y12 Inhibitors in Patients on Chronic Dialysis
- Age Modifies Intracranial and Gastrointestinal Bleeding Risk from P2Y12 Inhibitors in Patients Receiving Dialysis
- Left Atrial Appendage Occlusion vs Anticoagulants in Dialysis With Atrial Fibrillation
- Comparative Effectiveness and Safety of Oral P2Y12 Inhibitors in Patients on Chronic Dialysis
- Platelet Count and Platelet Volume in Patients with CKD
- Renal Biomarkers in Heart Failure
- Comparative Effectiveness and Safety of Oral P2Y12 Inhibitors in Patients on Chronic Dialysis
- Age Modifies Intracranial and Gastrointestinal Bleeding Risk from P2Y12 Inhibitors in Patients Receiving Dialysis
- P2Y12 Inhibitors Refill Gap Predicts Death in Medicare Beneficiaries on Chronic Dialysis
- Platelet-Dependent Inflammatory Dysregulation in Patients with Stages 4 or 5 Chronic Kidney Disease: A Mechanistic Clinical Study
- Ticagrelor inhibits platelet aggregation and reduces inflammatory burden more than clopidogrel in patients with stages 4 or 5 chronic kidney disease
- Higher Glycolysis in Circulating Leukocytes in Patients with CKD
Similar Researchers
Based on overlapping research topics